medigraphic.com
Medicina Universitaria

2007, Number 35

<< Back Next >>

Med Univer 2007; 9 (35)

Collection of peripherial hematopoyetic cells for allogenic transplantation with intermediate doses of filgrastim

Gutiérrez ACH, Martínez GOL, Salazar RR, González LO, Cantú RO, Gómez AD

Language: Spanish
References: 16
Page: 68-71
PDF size: 113.49 Kb.


ABSTRACT

Background: peripheral hematopoietic stem cells are a resource used to combat different diseases that require an allogenic transplantation. The most accepted method used to harvest these cells is the administration of 2 to 24 µg/kg of weight of a granulocyte colony-stimulating factor and perform an apheresis on the fourth, fifth or sixth day after using this stimulating factor in the donor.
Objective: determine the adequate dosage of the granulocyte colony-stimulating factor and the optimal day to perform one single apheresis.
Patients and method: 11 donors were included, who received granulocyte colony-stimulating factor in daily doses of 8 µg/kg of weight. During 4 days, 2 apheresis were done; one on the 4th and other on the 5th day after the stimulation. The harvest of peripheral hematopoietic stem cells for allogenic transplantation done from February 2003 to May 2004 in the University Hospital Dr. José E. Gonzalez of the UANL was retrospectively analyzed.
Results: in 63% of patients the amount of CD34+ cells harvested was significantly greater on the 5th day than on the 4th (3.10 x 106 vs 2.9 x 106), considering that the average plasmatic volume processed through apheresis was less the first time than in the second time (8,800 vs 14,080 mL).
Conclusions: One dose of 8 µg/kg of weight of G-CSF is effective to obtain the necessary amount of hematopoietic peripheral stem cells. An apheresis on the 5th day after the stimulation is enough to obtain the necessary amount of CD34+ cells that assure the hematological recovery of the transplantation patient. This procedure reduces the secondary effects of the factor and the apheresis, as well as the final cost of the transplantation.


REFERENCES

  1. Shimizu N, Asai T, Hashimoto S, Narita M, et al. Mobilization factors of peripheral blood stem cells in healthy donors. Ther Apher 2002;6:413-8.

  2. Gyger M, Sahovic E, Aslam M. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1998;92:3489-90.

  3. Anderlini P, Donato M, Chan KW, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the MD Anderson Cancer Center experience. Transfusion 1999;39:555-60.

  4. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996;88:2819-25.

  5. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997;89:2233-58.

  6. Cutler C, Antin JP. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 2001;19:108-17.

  7. Weaver CH, Birch R, Schwartzberg L, et al. CD34 Content of peripheral blood progenitor cells (PBPC) is the single most powerful predictor of recovery kinetics in patients receiving myeloablative high-dose chemotherapy and PBPC infusion. Blood 1994;84(Suppl.1):1388a.

  8. Tricot G, Jagannath S, Vesole D. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85,588-96.

  9. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883-8.

  10. McCullough J, Clay M, Herr G, et al. Effects of granulocyte colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999;39:1136-40.

  11. Becker PS, Wagle M, Matous S, et al. Spontaneus splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997;3;45-49.

  12. Singhal S, Powles R, Kulkarni S, Treleaven J, et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs. blood stem cell transplantation. Bone Marrow Transplant 2000;25(5):501-5.

  13. Anderlini P, Korbling M, Dale D, Gratwohl A, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997;90:903-8.

  14. Martinez C, Urbano-Ispizua A, Rozman C, Marin P, et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 1996;72:269-72.

  15. Anderlini P, Przepiorka D, Seong D, Miller P, et al. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol 1996;93:940-2.

  16. Fischmeister G, Gadner H. Granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor for collection of peripheral blood progenitor cells from healthy donors. Curr Opin Hematol 2000;7:150-55.




2020     |     www.medigraphic.com